Pulmonary hypertension (PH) is one of the most devastating cardiovascular diseases worldwide and it draws much attention from numerous scientists. As an indispensable part of pulmonary artery, smooth muscle cells are worthy of being carefully investigated. To elucidate the pathogenesis of PH, several theories focusing on pulmonary artery smooth muscle cells (PASMC), such as hyperproliferation, resistance to apoptosis, and cancer theory, have been proposed and widely studied. Here, we tried to summarize the studies, concentrating on the role of PASMC in the development of PH, feasible molecular basis to intervene, and potential treatment to PH.
1. Introduction
Pulmonary hypertension (PH) is a serious global health problem, which is characterized by progressing elevated pulmonary pressures and right heart failure, and mainly affects childbearing women [1]. The mean time from onset of symptoms to diagnosis is about 2 years, the mean survival time of idiopathic/heritable pulmonary arterial hypertension patients from treatment initiation is about 14.7 years, and the 10-year survival rates are 69.5% [2, 3]. Based on recent estimates, in the global population, the prevalence of PH is about 1%, while for individuals aged over 65 years, the number increases to 10%. What is more, about 80% of PH patients are living in developing countries [4].
The feature of PH is intense remodeling of small pulmonary arteries by myofibroblast and smooth muscle cell proliferation, and for familial pulmonary arterial hypertension, the bone morphogenetic protein type II receptor (BMPR-II) mutation in pulmonary artery smooth muscle cells contributes to abnormal growth responses to the transforming growth factor (TGF)-beta/bone morphogenetic protein (BMP) [5]. Compared to previous belief that vasoconstriction acts a vital role in PH pathogenesis [6, 7], there is a tendency to think that excessive proliferation and resistance to apoptosis of PASMC and pulmonary artery endothelial cells (PAEC) are the crucial components of pulmonary vascular remodeling [8]. PASMC has been widely proved to play an important role in the development of various types of pulmonary hypertension. Different mechanisms finally lead to uncontrolled proliferation of PASMC through apoptosis resistance, activated hypoxia-induced factor (HIF), HDAC modification, and inflammation, resulting in pulmonary hypertension [9, 10].
According to similar pathophysiological mechanisms, clinical presentation, haemodynamic characteristics, and therapeutic management, the clinical classification of PH is intended to categorize multiple clinical conditions into five groups [11]. Here, we mainly talk about WHO group 1 pulmonary arterial hypertension (PAH). To offer more suitable treatment and precisely evaluate patients’ clinical outcome, the following parameters appear to have the greatest predictive capability: functional class, six-minute walk distance (6MWD), N-terminal pro-brain natriuretic peptide/brain natriuretic peptide (NT-proBNP/BNP) levels, cardiac index, right atrial pressure, and mixed venous oxygen saturation (SvO2) [12, 13]. Specific drug treatment of WHO group 1 PAH by targeting the nitric oxide, endothelin, and prostaglandin pathways has been the standard since 2003. Recently, based on different risk stratification, monotherapy or dual-combination therapies, including macitentan and sildenafil, riociguat and bosentan, selexipag and endothelin receptor antagonist (ERA) or phosphodiesterase inhibitor (PDE5i), or both, are recommended [14, 15].
2. Histopathology of Lungs in PH2.1. Histology of Normal Lung Vessels
The major role of the right ventricle (RV) is to pump all the blood it receives per beat into the pulmonary circulation without elevating right atrial pressure. Normally, blood flow varies with minimum changes in pulmonary arterial pressure. Although the total compliance of the pulmonary circulation is about one-seventh that of the systemic circulation, it stores much less blood and has the ability to collapse pulmonary vessels as well as have them distended. Thus, the pulmonary circulation is able to accommodate increased blood volumes without increasing pulmonary artery pressure as much as would occur on the systemic circulation [16, 17].
2.2. Histopathology of PAH Lung Vessels
In 1958, Heath and Edwards [18] first described the histologic features of hypertensive pulmonary vascular structure changes into six grades in patients with congenital septal defects of the heart. The six grades included retention of fetal type pulmonary vessels, medial hypertrophy with cellular intimal reaction, progressive fibrous vascular occlusion, progressive generalized arterial dilatation with the formation of complex dilatation lesions (plexiform lesions), chronic dilatation with formation of numerous dilatation lesions and pulmonary hemosiderosis, and necrotizing arteritis. It is widely accepted that higher grade is related to worse pulmonary vessels and right heart function. Compared to the control groups, intima and intima plus media fractional thicknesses of pulmonary arteries were increased in the PAH group, in accordance with pulmonary haemodynamic measurements. There were remarkable perivascular inflammation in a mass of PAH lungs and correlated with intima plus media remodeling [19].
Pulmonary vasoconstriction caused by hypoxia was studied widely in PH [7]. As a result of global pulmonary hypoxic vasoconstriction, the right ventricular afterload could increase. Chronic hypoxia-induced PH is partly due to initial pulmonary artery contraction. Pulmonary artery pressures are higher in high-altitude dwellers with chronic mountain sickness, a syndrome including dyspnoea, fatigue, poor sleep, headache, and cyanosis. Hypoxic pulmonary vascular remodeling also contributes to PH and begins to develop within the first hours of hypoxic exposure. Hypoxia-induced PH in humans or animals is generally mild or moderate, but with a substantial afterload on the right ventricle during exercise. In vitro, hypoxia was reported to inhibit myocardial fibre contractility. Pulmonary vascular contraction plays an important role not only in hypoxic PH, but also in pulmonary arterial hypertension (PAH). Current pharmacological therapies for PAH mostly target pathways regulating endothelial factors with vasoconstrictive/vasodilatory and have made great achievements in improving the exercise capacity, haemodynamics, and time to clinical worsening of PAH patients.
It is increasingly believed that although vasospasm acts a role, pulmonary hypertension is an obstructive lung panvasculopathy and different forms of PH present with either a predominance of pulmonary arterial remodeling or vein remodeling or a variable contribution of both [20]. Obviously, there is medial and adventitial thickening of the pulmonary muscular and elastic vessels. The medial thickening is believed to result in hypertrophy and increased accumulation of smooth muscle cells as well as increased deposition of extracellular matrix proteins, predominantly collagen and elastin. The extent of structural changes, including SMC proliferation, hypertrophy, matrix protein production, and recruitment of adventitial or circulating cells, in the medial compartment of the pulmonary arterial wall partly determined the severity of chronic hypoxic pulmonary hypertension [21].
3. The Alteration of PASMC in PH
Data from post-mortem studies demonstrated medial hypertrophy, PASMC hyperproliferation, and muscle extension into distal arterioles, with important variability between individuals [22–25]. The accurate regulation of the balance between PASMC proliferation and apoptosis is significant in maintaining the normal integrity of structure and function in the pulmonary vessels. However, in severe angioproliferative PAH, this balance seems to be broken, following increased PASMC proliferation and decreased apoptosis, resulting in vessel wall thickening and vascular remodeling [26–31]. Contrast to previous belief that the relationship between pulmonary artery endothelial cells (PAEC) and PASMC is a simple one-way interaction from the endothelium to the PASMC, now it is more likely to believe that more complicated interactions exist between them [32–34]. Under abnormal or irritant conditions, the intricate interaction of PAEC and PASMC can be altered in the long term so that vascular proliferation and vasocontractility are enhanced further, which leads to PAH and right heart failure [35–38]. Owing to the characteristics of hyperproliferation and resistance to apoptosis of PASMC in PAH, there is an argument that PAH has something to do with cancer. At the molecular level, PASMC of PAH exhibits many features similar to cancer cells, which gives the chance to explore potential therapeutic treatments used in cancer to cure PAH [8, 39, 40].
4. Possible Pathways to Act on PASMC4.1. Role of Ion Channels
It is well known that ions play many important roles in cell potential, cell contraction, and pH homeostasis, which can influence the proliferation and apoptosis of PASMC. Some studies demonstrated that decrease of K+ channels affected the PASMC depolarization, then facilitated vascular remodeling, and inhibited PASMC apoptosis. In PAH rat models, restoration of K+ channels activity and expression, using dehydroepiandrosterone or dichloroacetate, reduced pulmonary vascular remodeling. However, the exact mechanisms by which K+ channels act on PASMC are still controversial [41–51]. Lv et al. found increased expression of MicroRNA-206 suppressed potassium voltage-gated channel subfamily A member 5 (Kv1.5) and promoted the PASMC proliferation [52].
The elevated concentration of intracellular Ca2+ was found in PAH animal models and patients. This kind of phenomenon was not realized through activation of voltage-gated calcium channels (VGCC), but by increase of canonical transient receptor potential (TRPC) proteins, which involved Ca2+-permeable nonselective cation channels (NSCCs). Increased abundance of NSCCs was detected in PAH rat models and patients and inhibition of NSCCs, either pharmacologically or by RNA silencing, effectively decreased the concentration of intracellular Ca2+ and proliferation of PASMC [53–61]. Song et al. reported that stromal interaction molecule 2 (STIM2) protein, a Ca2+ sensor in the sarcoplasmic reticulum (SR) membrane, may contribute to elevated intracellular Ca2+ [62]. What is more, Ca2+ could activate nuclear factor of activated T-cells (NFAT), then suppress K+ channels expression, and lead to PASMC hyperproliferation [63]. It was also proved that hypoxia can cooperate with intracellular Ca2+, which increased the expression of aquaporin 1 (AQP1), a membrane water channel, indispensable for PASMC migration. Increased AQP1 upregulated β-catenin and its target genes (such as c-Myc and cyclin D1), which accelerated the proliferation and migration of PASMC [64–66].
The normal operation of Na+/H+ exchange (NHE) is essential to keep pH homeostasis of PASMC [67, 68]. Studies showed that increased expression of NHE isoform 1 (NHE1) can promote the exchange, elevate the pH, and induce the proliferation and migration of PASMC. Although the specific mechanisms are still unclear, it may have something to do with p27 (a cyclin-dependent kinase inhibitor), E2F1 (a nuclear transcription factor), and cytoskeletal re-arrangement [69–75].
4.2. Crucial Molecules
When we talk about PAH, we should never miss hypoxia and hypoxia-inducible factors (HIF). Under the circumstances of hypoxia, increased expression and decreased degradation result in accumulation of HIF-1α. A lot of studies proved that HIF-1α can influence the PASMC proliferation and mediate pulmonary vascular remodeling, by acting on Ca2+, pH homeostasis, endothelin-1 (ET-1), vascular endothelial growth factor (VEGF), and Warburg effect [76–84].
Endothelin is secreted by endothelial cells and has three isoforms, among which endothelin-1 (ET-1) is the most widely expressed and mediates vascular contraction, cell migration, and proliferation. In terms to PASMC, ET-1 binds to ETA or ETB and then has an impact on decreased K+ channels, elevated intracellular Ca2+, and activation of NHE1 and Rho kinase (ROCK) signaling, leading to the migration and proliferation of PASMC [85–88].
5-Hydroxytryptamine (5-HT) is well known in depression mechanism and it also takes part in the development of PAH. 5-HT enters PASMC through serotonin transporter (SERT). The signaling cascades caused by 5-HT include increased reactive oxygen species and activation of mitogen-activated protein kinase (MAPK) and ROCK pathway, which regulate the expression of genes targeting cell growth and influence PASMC [89–93].
4.3. Important Pathways4.3.1. Rho Kinase
Rho kinase (ROCK) signaling pathway plays an indispensable part in vascular contraction and remodeling. Exposed to hypoxia, activation of ROCK in PASMC through Rho B (upstream activators of ROCK) could augment the proliferation and migration of PASMC, resulting in increased pulmonary vascular resistance. There were studies stating that long-term use of ROCK inhibitors could ameliorate vascular remodeling [94–103]. Abe et al. reported that PDGF activated ROCK, suppressed the translocation of Smad1 originally induced by bone morphogenetic protein 2 (BMP 2), and increased PASMC proliferation [104].
4.3.2. BMP Signaling
Bone morphogenetic protein receptor type 2 (BMPR2) mutations are present in patients with heritable and idiopathic PAH, which reminds us of BMP signaling’s significant role in the development of PAH. The mutation of BMPR2 could inhibit the antiproliferation effect of BMP2, leading to PAH. BMP can exert its function in a way of Smad dependent or independent. BMP/BMPR1 interacts with Smad1/5/8, then increasing their binding with Smad4, finally leading to elevated related genes expression. In other ways, BMP activates MAPK, PI3K/AKT, or protein kinase C (PKC) to influence PASMC. The impaired control of BMP signaling may be a common characteristic of PH no matter what the pathogenesis is [105–110] (Figure 1).
Molecular pathways in PASMC (1). ET-1: endothelin-1, 5-HT: serotonin, BMP: bone morphogenetic proteins, ET A/ET B endothelin receptor A/B, SERT: serotonin transporter, BMPR: bone morphogenetic proteins receptor, NHE: Na+/H+ exchanger, HIF: hypoxia-induced factor, ROCK: Rho kinase, PI3K/AKT: phosphatidylinositide 3-kinase/protein kinase B, PKC: protein kinase C.
4.3.3. Cancer Theories
As mentioned above, at the molecular level, PASMC of PAH exhibits many features similar to cancer cells, making it possible to explore potential therapeutic treatments used in cancer to cure PAH (reviewed in [40]). Studies showed increase of IL-6, monocyte chemotactic protein 1 (MCP-1), and tumor necrosis factor alpha (TNF-α) related to worse clinical outcomes in PAH patients. IL-6 knockout effectively ameliorated PAH in animal models. Platelet-derived growth factor (PDGF) mediated mitogenic signaling and thickening of the pulmonary vascular media. These growth factors and inflammatory mediators eventually have an impact on cell growth and survival by MEK/ERK, PI3K/AKT, or JAK/STAT3 pathways. In PASMC, it was reported that activation of STAT3 can upregulate the expression of proviral integration site for Moloney murine leukemia virus-1 (PIM-1) and then enhance NFAT-mediated transactivation, resulting in decreased K+ channels and increased intracellular Ca2+. In addition, activation of PI3K/AKT and JAK/STAT3 inhibited the transcription factor Forkhead box protein O1 (FOXO1), causing elevated Cyclin B1 and D1 and decreased p27, which promoted PASMC proliferation [48, 111–122].
Mammalian target of rapamycin (mTOR) signaling plays important roles in cell metabolism, cell proliferation, and survival. Together with other proteins, mTOR forms two independent complexes, mTORC1 (mTOR-Raptor) and mTORC2 (mTOR-Rictor). Activation of mTORC1 could enhance ribosomal protein S6 kinase beta-1 (S6K1) and suppress eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), which facilitates cell growth and proliferation. On the other hand, mTORC2 is more likely to respond to growth factors, increasing cell survival [123–125]. However, Tang et al. reported that mTORC1 and mTORC2 had different roles in the development of PAH. Inhibition of mTORC1 ameliorated pulmonary hypertension, while inhibition of mTORC2 facilitated spontaneous pulmonary hypertension and it may result from upregulation of PDGF receptors in PASMC [126].
The Hippo signaling pathway is believed to relate to controlling organ size. It is constitutive of a cascade of tumor suppressive kinases mammalian STE20-like protein kinase 1/2 (MST1/2) and large tumor suppressor homolog 1/2 (LATS1/2), while its downstream molecules include yes-associated protein 1 (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ). Inactivation of LATS1/2 leads to decrease of YAP and TAZ in cytoplasm and activation of HIF-1α and Notch3 pathways, which plays a deleterious role in the development of PAH [127–133].
Most cancer cells rely on aerobic glycolysis, instead of depending on mitochondrial oxidative phosphorylation to generate energy, a phenomenon termed “the Warburg effect.” This effect also can be seen in PASMC and PAH. Driven by HIF activation, augmented glycolysis is characterized by elevated expression of pivotal proteins in its pathway, such as glucose transporters, hexokinase, pyruvate dehydrogenase kinase (PDK), lactate dehydrogenase (LDH), and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3). By interacting with PI3K/AKT, ERK1/2, and HIF-1α and altering the morphology and subcellular distribution of mitochondria, Warburg effect increases the proliferation of PASMC in PAH [10, 134–144].
4.3.4. Other Pathways
Peroxisome proliferator-activated receptor γ (PPARγ) regulates mitochondrial gene expression and biogenesis. Loss of PPARγ leads to derangement in mitochondrial structure and function, which has a harmful impact on PASMC and PAH [145]. Xie et al. stated that leptin effectively ameliorated pulmonary vascular remodeling and PAH, via activation of ERK1/2 and elevated expression of early growth response-1 (Egr-1), resulting in loss of PPARγ [146]. In addition, Li et al. reported that activating prostanoid EP4 receptor (EP4) also decreased the expression of PPARγ through protein kinase A (PKA) pathway and attenuated pulmonary arterial remodeling [147] (Figure 2).
Molecular pathways in PASMC (2). PDGF: platelet-derived growth factor, IL-6: interleukin-6, TNF-α: tumor necrosis factor-α, PPAR-γ: peroxisome proliferator-activated receptor-γ, MST 1/2: mammalian sterile 20-like kinases 1/2, Egr-1: early growth response-1, MEK/ERK: mitogen-activated protein kinase/extracellular-signal regulated kinase, PI3K/AKT: phosphatidylinositide 3-kinase/protein kinase B, JAK/STAT3: Janus kinase/signal transducer and activator of transcription 3, LATS 1/2: large tumor suppressor kinases 1/2, mTOR: mechanistic target of rapamycin, FOXO1: forkhead box protein O1, YAP: yes-associated protein, TAZ: transcriptional coactivator with PDZ-binding motif, 4E-BP1: eukaryotic translation initiation factor 4E-binding protein 1, S6K1: ribosomal protein S6 kinase beta-1, HIF-1α: hypoxia-induced factor-1α.
Cyclin-dependent kinases (CDK) are crucial regulators of cell cycle and proliferation. Dinaciclib and palbociclib inhibited specific CDK and decreased PASMC proliferation via cell cycle arrest and interacted with the downstream CDK-Rb (retinoblastoma protein)-E2F signaling pathway, offering a potential strategy in PAH [148]. Sphingosine kinase 1 (SphK1) is a lipid kinase for phosphorylating sphingosine to generate sphingosine-1-phosphate (S1P). SphK1/S1P have been reported to relate to cell proliferation, migration, and survival. TGF-β1 could phosphorylate Smad2/3 and then elevate the expression of SphK1 and S1P, which activates Notch3 pathway to promote PASMC proliferation [149]. What is more, Sysol et al. reported that decreased micro-RNA-1 induced by hypoxia had an effect on the development of PAH via regulation of sphingosine kinase 1 [150].
5. Potential Treatment to PAH
While calcium channel blockers, endothelin receptor antagonists, phosphodiesterase type 5 inhibitors and guanylate cyclase stimulators, prostacyclin analogues, and prostacyclin receptor agonists are the classical specific drug therapies for PAH, their effects still are limited and unsatisfactory. Based on the molecular pathways mentioned above, tyrosine kinase inhibitors (platelet-derived growth factor inhibitors) and serotonin antagonists are being explored, but present outcomes are not ideal. Moreover, ROCK inhibitors, VEGF receptor inhibitors, stem cell therapy, mTOR inhibitors, PPAR-γ agonist, and strategies aiming at Warburg effect are all in the early phase of research [15, 142–144, 151, 152].
6. Summary
Although the treatment for pulmonary hypertension has achieved great improvement, it is still not that satisfactory. Owing to its indispensable role in the development of pulmonary hypertension, PASMC becomes the research hot spot in PH. Further elucidating the molecular basis of PASMC, including ion channels, HIF, ET-1, ROCK, BMP, PPAR-γ, and Warburg effect, could bring hope to PH treatment.
Conflicts of Interest
The authors declare that there are no conflicts of interest.
McLaughlinV. V.ArcherS. L.BadeschD. B.ACCF/AHA 2009 expert consensus document on pulmonary hypertension200953171573161910.1016/j.jacc.2009.01.0042-s2.0-64849109410RichS.DantzkerD. R.AyresS. M.Primary pulmonary hypertension. A national prospective study1987107221622310.7326/0003-4819-107-2-2162-s2.0-0023615359OgawaA.SatohT.TamuraY.FukudaK.MatsubaraH.Survival of Japanese patients with idiopathic/heritable pulmonary arterial hypertension201711991479148410.1016/j.amjcard.2017.01.0152-s2.0-85014189908HoeperM. M.HumbertM.SouzaR.A global view of pulmonary hypertension20164430632210.1016/s2213-2600(15)00543-32-s2.0-84960466895MorrellN. W.Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling?20063868068610.1513/pats.200605-118sf2-s2.0-33751227533MotleyH. L.CournandA.WerkoL.HimmelsteinA.DresdaleandD.The influence of short periods of induced acute anoxia upon pulmonary artery pressures in man1947150231532010.1152/ajplegacy.1947.150.2.3152-s2.0-0000707862NaeijeR.DedobbeleerC.Pulmonary hypertension and the right ventricle in hypoxia20139881247125610.1113/expphysiol.2012.0691122-s2.0-84880698933BoucheratO.VitryG.TrinhI.PaulinR.ProvencherS.BonnetS.The cancer theory of pulmonary arterial hypertension20177228529910.1177/20458932177014382-s2.0-85021285812PerezV. A. D. J.Molecular pathogenesis and current pathology of pulmonary hypertension201621323925710.1007/s10741-015-9519-22-s2.0-84951738052PaulinR.MichelakisE. D.The metabolic theory of pulmonary arterial hypertension2014115114816410.1161/circresaha.115.3011302-s2.0-84902968590SimonneauG.MontaniD.CelermajerD. S.Haemodynamic definitions and updated clinical classification of pulmonary hypertension2019531180191310.1183/13993003.01913-20182-s2.0-85060524284SitbonO.BenzaR. L.BadeschD. B.Validation of two predictive models for survival in pulmonary arterial hypertension201546115216410.1183/09031936.000044142-s2.0-84928964408BouclyA.WeatheraldJ.HumbertM.SitbonO.Risk assessment in pulmonary arterial hypertension20183CondonD. F.NickelN. P.AndersonR.MirzaS.PerezV. A. D. J.The 6th world symposium on pulmonary hypertension: what’s old is new2019888810.12688/f1000research.18811.12-s2.0-85067641454GalieN.HumbertM.VachieryJ.-L.2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (ESC) and the European respiratory society (ERS): endorsed by: association for European paediatric and congenital cardiology (AEPC), international society for heart and lung transplantation (ISHLT)20163716711910.1093/eurheartj/ehv3172-s2.0-84958184473PinskyM. R.The right ventricle: interaction with the pulmonary circulation201620126610.1186/s13054-016-1440-02-s2.0-84992080001HeY.-Y.LiuC.-L.LiX.LiR.-J.WangL.-L.HeK.-L.Salubrinal attenuates right ventricular hypertrophy and dysfunction in hypoxic pulmonary hypertension of rats20168719019810.1016/j.vph.2016.09.0092-s2.0-85001099585HeathD.EdwardsJ. E.The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects195818453354710.1161/01.cir.18.4.533StacherE.GrahamB. B.HuntJ. M.Modern age pathology of pulmonary arterial hypertension2012186326127210.1164/rccm.201201-0164oc2-s2.0-84864522564TuderR. M.ArcherS. L.DorfmullerP.Relevant issues in the pathology and pathobiology of pulmonary hypertension20136225D4D1210.1016/j.jacc.2013.10.0252-s2.0-84890753066StenmarkK. R.FaganK. A.FridM. G.Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms200699767569110.1161/01.res.0000243584.45145.3f2-s2.0-33749345684NaeyeR. L.Hypoxemia and pulmonary hypertension. A study of the pulmonary vasculature196171447452NaeyeR. L.Children at high altitude: pulmonary and renal abnormalities1965161333810.1161/01.res.16.1.332-s2.0-0007153930Arias-StellaJ.SaldanaM.The terminal portion of the pulmonary arterial tree in people native to high altitudes196328591592510.1161/01.cir.28.5.9152-s2.0-0001507064HeathD.SmithP.RiosD. J.WilliamsD.HarrisP.Small pulmonary arteries in some natives of La Paz, Bolivia198136859960410.1136/thx.36.8.5992-s2.0-0019479960RabinovitchM.Elastase and the pathobiology of unexplained pulmonary hypertension19981143213S224S10.1378/chest.114.3_supplement.213s2-s2.0-0031671673RubinL. J.Cellular and molecular mechanisms responsible for the pathogenesis of primary pulmonary hypertension199927S1819419710.1002/(sici)1099-0496(1999)27:18+<194::aid-ppul63>3.0.co;2-6WagenvoortC. A.The pathology of primary pulmonary hypertension19704WohrleyJ. D.FridM. G.MoiseevaE. P.OrtonE. C.BelknapJ. K.StenmarkK. R.Hypoxia selectively induces proliferation in a specific subpopulation of smooth muscle cells in the bovine neonatal pulmonary arterial media199596127328110.1172/jci1180312-s2.0-0029146280DiezJ.FortunoM. A.ZalbaG.Altered regulation of smooth muscle cell proliferation and apoptosis in small arteries of spontaneously hypertensive rats199819G29G33SakaoS.TatsumiK.VoelkelN. F.Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation200910110.1186/1465-9921-10-952-s2.0-73949089232BalcellsM.MartorellJ.OliveC.Smooth muscle cells orchestrate the endothelial cell response to flow and injury2010121202192219910.1161/circulationaha.109.8772822-s2.0-77953023925BillaudM.LohmanA. W.JohnstoneS. R.BiwerL. A.MutchlerS.IsaksonB. E.Regulation of cellular communication by signaling microdomains in the blood vessel wall201466251356910.1124/pr.112.0073512-s2.0-84897543452Nogueira-FerreiraR.FerreiraR.Henriques-CoelhoT.Cellular interplay in pulmonary arterial hypertension: implications for new therapies20141843588589310.1016/j.bbamcr.2014.01.0302-s2.0-84894296768IvyD. D.AbmanS. H.BarstR. J.Pediatric pulmonary hypertension20136225D117D12610.1016/j.jacc.2013.10.0282-s2.0-84890631176AustinE. D.KawutS. M.GladwinM. T.AbmanS. H.Pulmonary hypertension: NHLBI workshop on the primary prevention of chronic lung diseases2014113S178S18510.1513/annalsats.201312-443ld2-s2.0-84899129232GuignabertC.TuL.GirerdB.New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication2015147252953710.1378/chest.14-08622-s2.0-84928079676GaoY.ChenT.RajJ. U.Endothelial and smooth muscle cell interactions in the pathobiology of pulmonary hypertension201654445146010.1165/rcmb.2015-0323tr2-s2.0-84963759635VoelkelN. F.CoolC.LeeS. D.WrightL.GeraciM. W.TuderR. M.Primary pulmonary hypertension between inflammation and cancer19981143225S230S10.1378/chest.114.3_supplement.225s2-s2.0-0031671780GuignabertC.TuL.HiressM. L.Pathogenesis of pulmonary arterial hypertension: lessons from cancer20132213054355110.1183/09059180.000075132-s2.0-84888811646SuzukiH.TwarogB. M.Membrane properties of smooth muscle cells in pulmonary hypertensive rats19822425H907H91510.1152/ajpheart.1982.242.5.h907ShimodaL. A.PolakJ.Hypoxia. 4. Hypoxia and ion channel function20113005C951C96710.1152/ajpcell.00512.20102-s2.0-79955558300YuanJ. X.AldingerA. M.JuhaszovaM.Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension199898141400140610.1161/01.cir.98.14.14002-s2.0-0032491187BurgE. D.RemillardC. V.YuanJ. X.-J.Potassium channels in the regulation of pulmonary artery smooth muscle cell proliferation and apoptosis: pharmacotherapeutic implications20081531S99S11110.1038/sj.bjp.07076352-s2.0-40349110969MichelakisE. D.McMurtryM. S.WuX.-C.Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels2002105224425010.1161/hc0202.1019742-s2.0-0037080541BonnetS.MichelakisE. D.PorterC. J.An abnormal mitochondrial-hypoxia inducible factor-1α-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension2006113222630264110.1161/circulationaha.105.6090082-s2.0-33745155785YuanX.-J.WangJ.JuhaszovaM.GaineS. P.RubinL. J.Attenuated K+ channel gene transcription in primary pulmonary hypertension1998351910472672710.1016/s0140-6736(05)78495-62-s2.0-0032492407BonnetS.RochefortG.SutendraG.The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted200710427114181142310.1073/pnas.06104671042-s2.0-34547456414PozegZ. I.MichelakisE. D.McMurtryM. S.In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats2003107152037204410.1161/01.cir.0000062688.76508.b32-s2.0-0037461359BonnetS.Dumas-De-La-RoqueE.BegueretH.Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension2003100169488949310.1073/pnas.16337241002-s2.0-0041422166McMurtryM. S.BonnetS.WuX.Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis200495883084010.1161/01.res.0000145360.16770.9f2-s2.0-6344257102LvY.FuL.ZhangZ.Increased expression of MicroRNA-206 inhibits potassium voltage-gated channel subfamily A member 5 in pulmonary arterial smooth muscle cells and is related to exaggerated pulmonary artery hypertension following intrauterine growth retardation in rats201982e1045610.1161/jaha.118.0104562-s2.0-85059904542WangJ.WeigandL.LuW.SylvesterJ. T.SemenzaG. L.ShimodaL. A.Hypoxia inducible factor 1 mediates hypoxia-induced TRPC expression and elevated intracellular Ca2+ in pulmonary arterial smooth muscle cells200698121528153710.1161/01.res.0000227551.68124.982-s2.0-33746543743LinM.-J.LeungG. P. H.ZhangW.-M.Chronic hypoxia-induced upregulation of store-operated and receptor-operated Ca2+ channels in pulmonary arterial smooth muscle cells: a novel mechanism of hypoxic pulmonary hypertension200495549650510.1161/01.res.0000138952.16382.ad2-s2.0-4444352981GolovinaV. A.PlatoshynO.BaileyC. L.Upregulated TRP and enhanced capacitative Ca2+ entry in human pulmonary artery myocytes during proliferation20012802H746H75510.1152/ajpheart.2001.280.2.h746LandsbergJ. W.YuanJ. X.-J.Calcium and TRP channels in pulmonary vascular smooth muscle cell proliferation2004192445010.1152/nips.01457.20032-s2.0-2342483718LeggettK.MaylorJ.UndemC.Hypoxia-induced migration in pulmonary arterial smooth muscle cells requires calcium-dependent upregulation of aquaporin 120123034L343L35310.1152/ajplung.00130.20122-s2.0-84865137448LiuX.-R.ZhangM.-F.YangN.Enhanced store-operated Ca2+ entry and TRPC channel expression in pulmonary arteries of monocrotaline-induced pulmonary hypertensive rats20123021C77C8710.1152/ajpcell.00247.20112-s2.0-83655197507SongM. Y.MakinoA.YuanJ. X.-J.STIM2 contributes to enhanced store-operated Ca entry in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension201111849410.4103/2045-8932.781062-s2.0-84855317520YuY.FantozziI.RemillardC. V.Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension200410138138611386610.1073/pnas.04059081012-s2.0-4644290321KunichikaN.LandsbergJ. W.YuY.Bosentan inhibits transient receptor potential channel expression in pulmonary vascular myocytes2004170101101110710.1164/rccm.200312-1668oc2-s2.0-8444223158SongS.CarrS. G.McDermottK. M.STIM2 (stromal interaction molecule 2)-mediated increase in resting cytosolic free Ca2+ concentration stimulates PASMC proliferation in pulmonary arterial hypertension201871351852910.1161/hypertensionaha.117.105032-s2.0-85044364114HeR.-L.WuZ.-J.LiuX.-R.GuiL.-X.WangR.-X.LinM.-J.Calcineurin/NFAT signaling modulates pulmonary artery smooth muscle cell proliferation, migration and apoptosis in monocrotaline-induced pulmonary arterial hypertension rats201849117218910.1159/0004928522-s2.0-85052959328SaadounS.PapadopoulosM. C.Hara-ChikumaM.VerkmanA. S.Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption2005434703478679210.1038/nature034602-s2.0-17144379334MonzaniE.BazzottiR.PeregoC.PortaC. A. M. L.AQP1 is not only a water channel: it contributes to cell migration through Lin7/beta-catenin200947e616710.1371/journal.pone.00061672-s2.0-67650230936YunX.JiangH.LaiN.WangJ.ShimodaL. A.Aquaporin 1-mediated changes in pulmonary arterial smooth muscle cell migration and proliferation involve beta-catenin20173135L889L89810.1152/ajplung.00247.20162-s2.0-85033366982MaddenJ. A.RayD. E.KellerP. A.KleinmanJ. G.Ion exchange activity in pulmonary artery smooth muscle cells: the response to hypoxia20012802L264L27110.1152/ajplung.2001.280.2.l264QuinnD. A.HoneymanT. W.JosephP. M.ThompsonB. T.HalesC. A.ScheidC. R.Contribution of Na+/H+ exchange to pH regulation in pulmonary artery smooth muscle cells19915658659110.1165/ajrcmb/5.6.5862-s2.0-0026296977QuinnD. A.DahlbergC. G.BonventreJ. P.The role of Na+/H+ exchange and growth factors in pulmonary artery smooth muscle cell proliferation199614213914510.1165/ajrcmb.14.2.86302632-s2.0-0030077602RiosE. J.FallonM.WangJ.ShimodaL. A.Chronic hypoxia elevates intracellular pH and activates Na+/H+ exchange in pulmonary arterial smooth muscle cells20052895L867L87410.1152/ajplung.00455.20042-s2.0-27144433158ShimodaL. A.FallonM.PisarcikS.WangJ.SemenzaG. L.HIF-1 regulates hypoxic induction of NHE1 expression and alkalinization of intracellular pH in pulmonary arterial myocytes20062915L941L94910.1152/ajplung.00528.20052-s2.0-33751117499QuinnD. A.DuH.-K.ThompsonB. T.HalesC. A.Amiloride analogs inhibit chronic hypoxic pulmonary hypertension199815741263126810.1164/ajrccm.157.4.9704106YuL.QuinnD. A.GargH. G.HalesC. A.Deficiency of the NHE1 gene prevents hypoxia-induced pulmonary hypertension and vascular remodeling2008177111276128410.1164/rccm.200710-1522oc2-s2.0-44449095608YuL.HalesC. A.Silencing of sodium-hydrogen exchanger 1 attenuates the proliferation, hypertrophy, and migration of pulmonary artery smooth muscle cells via E2F1201145592393010.1165/rcmb.2011-0032oc2-s2.0-80555143052DenkerS. P.HuangD. C.OrlowskiJ.FurthmayrH.BarberD. L.Direct binding of the Na-H exchanger NHE1 to ERM proteins regulates the cortical cytoskeleton and cell shape independently of H+ translocation2000661425143610.1016/s1097-2765(00)00139-82-s2.0-0034503095SemenzaG. L.Pulmonary vascular responses to chronic hypoxia mediated by hypoxia-inducible factor 1200521687010.1513/pats.200404-029ms2-s2.0-17644423994PrabhakarN. R.SemenzaG. L.Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 22012923967100310.1152/physrev.00030.20112-s2.0-84864131464YuA. Y.ShimodaL. A.IyerN. V.Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha1999103569169610.1172/jci59122-s2.0-0033104847ShimodaL. A.SemenzaG. L.HIF and the lung: role of hypoxia-inducible factors in pulmonary development and disease2011183215215610.1164/rccm.201009-1393pp2-s2.0-78751690547ShimodaL. A.55th Bowditch Lecture: effects of chronic hypoxia on the pulmonary circulation: role of HIF-1201211391343135210.1152/japplphysiol.00843.20122-s2.0-84875741389IyerN. V.KotchL. E.AganiF.Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha199812214916210.1101/gad.12.2.1492-s2.0-15444342958ShimodaL. A.Hypoxic regulation of ion channels and transporters in pulmonary vascular smooth muscle201066122123510.1007/978-1-60761-500-2_142-s2.0-77951216444WangC.-C.YingL.BarnesE. A.Pulmonary artery smooth muscle cell HIF-1alpha regulates endothelin expression via microRNA-54320183153L422L43110.1152/ajplung.00475.20172-s2.0-85053292764HeX.SongS.AyonR. J.Hypoxia selectively upregulates cation channels and increases cytosolic [Ca2+] in pulmonary, but not coronary, arterial smooth muscle cells20183144C504C51710.1152/ajpcell.00272.20172-s2.0-85045509876ShaoD.ParkJ. E. S.WortS. J.The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension201163650451110.1016/j.phrs.2011.03.0032-s2.0-79958069658ShimodaL. A.ShamJ. S. K.LiuQ.SylvesterJ. T.Acute and chronic hypoxic pulmonary vasoconstriction: a central role for endothelin-1?200213219310610.1016/s1569-9048(02)00052-62-s2.0-0037158630WhitmanE. M.PisarcikS.LukeT.Endothelin-1 mediates hypoxia-induced inhibition of voltage-gated K+ channel expression in pulmonary arterial myocytes20082942L309L31810.1152/ajplung.00091.20072-s2.0-39149127581HuetschJ. C.WalkerJ.UndemC.Rho kinase and Na+/H+ exchanger mediate endothelin-1-induced pulmonary arterial smooth muscle cell proliferation and migration201869e1369810.14814/phy2.136982-s2.0-85046996880MacLeanM. R.AlexanderD.StirratA.Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat2000130220120410.1038/sj.bjp.07033142-s2.0-0013023197EddahibiS.FabreV.BoniC.Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells. Relationship with the mitogenic action of serotonin199984332933610.1161/01.res.84.3.3292-s2.0-0032971293MairK. M.MacLeanM. R.MorecroftI.DempsieY.PalmerT. M.Novel interactions between the 5-HT transporter, 5-HT1B receptors and Rho kinase in vivo and in pulmonary fibroblasts2008155460661610.1038/bjp.2008.3102-s2.0-53849083055MacleanM. R.DempsieY.The serotonin hypothesis of pulmonary hypertension revisited201066130932210.1007/978-1-60761-500-2_202-s2.0-77951227152MacLeanM. R.The serotonin hypothesis in pulmonary hypertension revisited: targets for novel therapies (2017 Grover Conference Series)20188220458940187591210.1177/20458940187591252-s2.0-85049887598OkaM.HommaN.Taraseviciene-StewartL.Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats2007100692392910.1161/01.res.0000261658.12024.182-s2.0-34147189502WardJ. P.McMurtryI. F.Mechanisms of hypoxic pulmonary vasoconstriction and their roles in pulmonary hypertension: new findings for an old problem20099328729610.1016/j.coph.2009.02.0062-s2.0-66049112085FirthA. L.ChoiI. W.ParkW. S.Animal models of pulmonary hypertension: rho kinase inhibition20121093677510.1016/j.pbiomolbio.2012.05.0092-s2.0-84864566286OkaM.FaganK. A.JonesP. L.McMurtryI. F.Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension2008155444445410.1038/bjp.2008.2392-s2.0-53849089211YangX.LeeP. J.LongL.TrembathR. C.MorrellN. W.BMP4 induces HO-1 via a Smad-independent, p38MAPK-dependent pathway in pulmonary artery myocytes200737559860510.1165/rcmb.2006-0360oc2-s2.0-35348967735GerthofferW. T.Mechanisms of vascular smooth muscle cell migration2007100560762110.1161/01.res.0000258492.96097.472-s2.0-33947715935LiuY.SuzukiY. J.DayR. M.FanburgB. L.Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin200495657958610.1161/01.res.0000141428.53262.a42-s2.0-4644248958FukumotoY.MatobaT.ItoA.Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension200591339139210.1136/hrt.2003.0294702-s2.0-14244260105IshikuraK.YamadaN.ItoM.Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension200670217417810.1253/circj.70.1742-s2.0-31644431508FaganK. A.OkaM.BauerN. R.Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase20042874L656L66410.1152/ajplung.00090.20032-s2.0-4544388803AbeK.ShimokawaH.MorikawaK.Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats200494338539310.1161/01.res.0000111804.34509.942-s2.0-10744222390WeiH.ZhangD.LiuL.XiaW.LiF.Rho signaling pathway enhances proliferation of PASMCs by suppressing nuclear translocation of Smad1 in PAH20191717810.3892/etm.2018.6942SieberC.KopfJ.HiepenC.KnausP.Recent advances in BMP receptor signaling2009205-634335510.1016/j.cytogfr.2009.10.0072-s2.0-70649083092DaviesR. J.MorrellN. W.Molecular mechanisms of pulmonary arterial hypertension: role of mutations in the bone morphogenetic protein type II receptor200813461271127710.1378/chest.08-13412-s2.0-57349188499DuL.SullivanC. C.ChuD.Signaling molecules in nonfamilial pulmonary hypertension2003348650050910.1056/nejmoa0216502-s2.0-0037421604TakahashiH.GotoN.KojimaY.Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension20062903L450L45810.1152/ajplung.00206.20052-s2.0-33644958041LoweryJ. W.CaesteckerM. P. D.BMP signaling in vascular development and disease201021428729810.1016/j.cytogfr.2010.06.0012-s2.0-77956404810HassounP. M.MouthonL.BarberaJ. A.Inflammation, growth factors, and pulmonary vascular remodeling2009541S10S1910.1016/j.jacc.2009.04.0062-s2.0-67649844313RabinovitchM.GuignabertC.HumbertM.NicollsM. R.Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension2014115116517510.1161/circresaha.113.3011412-s2.0-84902950876ShalapourS.KarinM.Immunity, inflammation, and cancer: an eternal fight between good and evil201512593347335510.1172/jci800072-s2.0-84941660341HumbertM.MontiG.BrenotF.Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension199515151628163110.1164/ajrccm.151.5.77356242-s2.0-0029062419SelimovicN.BerghC.-H.AnderssonB.SakinieneE.CarlstenH.RundqvistB.Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension200934366266810.1183/09031936.001749082-s2.0-70349157154SavaleL.TuL.RideauD.Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice200910110.1186/1465-9921-10-62-s2.0-61549104663SteinerM. K.SyrkinaO. L.KolliputiN.MarkE. J.HalesC. A.WaxmanA. B.Interleukin-6 overexpression induces pulmonary hypertension2009104223624410.1161/circresaha.108.1820142-s2.0-59849118025PaulinR.CourboulinA.MelocheJ.Signal transducers and activators of transcription-3/pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension2011123111205121510.1161/circulationaha.110.9633142-s2.0-79953043420BonnetS.BelusA.HyvelinJ.-M.RouxE.MarthanR.SavineauJ.-P.Effect of chronic hypoxia on agonist-induced tone and calcium signaling in rat pulmonary artery20012811L193L20110.1152/ajplung.2001.281.1.l193BonnetS.ArcherS. L.Allalunis-TurnerJ.A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth2007111375110.1016/j.ccr.2006.10.0202-s2.0-33846002728SavaiR.Al-TamariH. M.SeddingD.Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension201420111289130010.1038/nm.36952-s2.0-84922391532DansenT. B.BurgeringB. M. T.Unravelling the tumor-suppressive functions of FOXO proteins200818942142910.1016/j.tcb.2008.07.0042-s2.0-49849093007LaplanteM.SabatiniD. M.mTOR signaling in growth control and disease2012149227429310.1016/j.cell.2012.03.0172-s2.0-84859778293GoncharovaE. A.mTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospects20132751796180710.1096/fj.12-2222242-s2.0-84877121075GoncharovD. A.KudryashovaT. V.ZiaiH.Mammalian target of rapamycin complex 2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial hypertension2014129886487410.1161/circulationaha.113.0045812-s2.0-84896694447TangH.WuK.WangJ.Pathogenic role of mTORC1 and mTORC2 in pulmonary hypertension20183674476210.1016/j.jacbts.2018.08.0092-s2.0-85059098492HalderG.JohnsonR. L.Hippo signaling: growth control and beyond2011138192210.1242/dev.0455002-s2.0-78650724753EhmerU.SageJ.Control of proliferation and cancer growth by the Hippo signaling pathway201614212714010.1158/1541-7786.mcr-15-03052-s2.0-84958164916ZanconatoF.ForcatoM.BattilanaG.Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth20151791218122710.1038/ncb32162-s2.0-84940587069BerteroT.OldhamW. M.CottrillK. A.Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension201612693313333510.1172/jci863872-s2.0-84987849527BerteroT.CottrillK. A.LuY.Matrix remodeling promotes pulmonary hypertension through feedback mechanoactivation of the YAP/TAZ-miR-130/301 circuit20151351016103210.1016/j.celrep.2015.09.0492-s2.0-84947433351KudryashovaT. V.GoncharovD. A.PenaA.HIPPO-Integrin-linked kinase cross-talk controls self-sustaining proliferation and survival in pulmonary hypertension2016194786687710.1164/rccm.201510-2003oc2-s2.0-84992417017BoucheratO.BonnetS.PaulinR.The HIPPO-thesis of pulmonary HYPERtension2016194778778910.1164/rccm.201604-0741ed2-s2.0-84992412594KroemerG.PouyssegurJ.Tumor cell metabolism: cancer’s Achilles’ heel200813647248210.1016/j.ccr.2008.05.0052-s2.0-44449147036SutendraG.MichelakisE. D.The metabolic basis of pulmonary arterial hypertension201419455857310.1016/j.cmet.2014.01.0042-s2.0-84897568503LiM.RiddleS.ZhangH.Metabolic reprogramming regulates the proliferative and inflammatory phenotype of adventitial fibroblasts in pulmonary hypertension through the transcriptional corepressor C-terminal binding protein-12016134151105112110.1161/circulationaha.116.0231712-s2.0-84986216601Plecita-HlavataL.TauberJ.LiM.Constitutive reprogramming of fibroblast mitochondrial metabolism in pulmonary hypertension2016551475710.1165/rcmb.2015-0142oc2-s2.0-84988951415DromparisP.PaulinR.SutendraG.QiA. C.BonnetS.MichelakisE. D.Uncoupling protein 2 deficiency mimics the effects of hypoxia and endoplasmic reticulum stress on mitochondria and triggers pseudohypoxic pulmonary vascular remodeling and pulmonary hypertension2013113212613610.1161/circresaha.112.3006992-s2.0-84880569655SutendraG.DromparisP.WrightP.The role of Nogo and the mitochondria-endoplasmic reticulum unit in pulmonary hypertension201138855r88rAl-MehdiA.-B.PastukhV. M.SwigerB. M.Perinuclear mitochondrial clustering creates an oxidant-rich nuclear domain required for hypoxia-induced transcription20125231a4710.1126/scisignal.20027122-s2.0-84863664040HeidenM. G. V.CantleyL. C.ThompsonC. B.Understanding the Warburg effect: the metabolic requirements of cell proliferation200932459301029103310.1126/science.11608092-s2.0-66249108601DaiJ.ZhouQ.ChenJ.Rexius-HallM. L.RehmanJ.ZhouG.Alpha-enolase regulates the malignant phenotype of pulmonary artery smooth muscle cells via the AMPK-Akt pathway201891385010.1038/s41467-018-06376-x2-s2.0-85053730416ParraV.Bravo-SaguaR.Norambuena-SotoI.Inhibition of mitochondrial fission prevents hypoxia-induced metabolic shift and cellular proliferation of pulmonary arterial smooth muscle cells20171863112891290310.1016/j.bbadis.2017.07.0182-s2.0-85030674506KovacsL.CaoY.HanW.PFKFB3 in smooth muscle promotes vascular remodeling in pulmonary arterial hypertension2019200561762710.1164/rccm.201812-2290oc2-s2.0-85068265626YeligarS. M.KangB.-Y.BijliK. M.PPARgamma regulates mitochondrial structure and function and human pulmonary artery smooth muscle cell proliferation201858564865710.1165/rcmb.2016-0293oc2-s2.0-85046685013XieX.LiS.ZhuY.Egr-1 mediates leptin-induced PPARgamma reduction and proliferation of pulmonary artery smooth muscle cells201829335636210.1091/mbc.e17-03-01412-s2.0-85041440089LiH.-H.HsuH.-H.ChangG.-J.Prostanoid EP4 agonist L-902, 688 activates PPARgamma and attenuates pulmonary arterial hypertension20183143L349L35910.1152/ajplung.00245.20172-s2.0-85042885711WeissA.NeubauerM. C.YeraboluD.Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension2019101220410.1038/s41467-019-10135-x2-s2.0-85065798890WangJ.FengW.LiF.SphK1/S1P mediates TGF-β1-induced proliferation of pulmonary artery smooth muscle cells and its potential mechanisms20199120458940188169710.1177/20458940188169772-s2.0-85058482513SysolJ. R.ChenJ.SinglaS.Micro-RNA-1 is decreased by hypoxia and contributes to the development of pulmonary vascular remodeling via regulation of sphingosine kinase 120183143L461L47210.1152/ajplung.00057.20172-s2.0-85043770024LuoL.ZhengW.LianG.Combination treatment of adipose-derived stem cells and adiponectin attenuates pulmonary arterial hypertension in rats by inhibiting pulmonary arterial smooth muscle cell proliferation and regulating the AMPK/BMP/Smad pathway20171516010.3892/ijmm.2017.32262-s2.0-85044927290XiaJ.YangL.DongL.Cefminox, a dual agonist of prostacyclin receptor and peroxisome proliferator-activated receptor-gamma identified by virtual screening, has therapeutic efficacy against hypoxia-induced pulmonary hypertension in rats2018913410.3389/fphar.2018.001342-s2.0-85042551561